Presentation delivered at the annual general meeting of Pistoia members. Describes the results of board member elections, the state of the Alliance's project portfolio, progress over the past year, and insights from new member Constellation Technologies about why they joined the Alliance.

1. September 2011 The Pistoia AllianceAnnual General Meeting - 2011

2. 2 Welcome

3. 3

4. Please mute your line unless you want to ask a question

5. September 2011 The Pistoia AllianceMinutes of 2010 AGM

6. Actions from 2010 Minutes Action Items: The board will work with the Operational Team to flesh out other ideas, and will talk reach out to the wider network to further explore these ideas. Ashley to work with the people who proposed these projects to develop PowerPoint presentations that can be used to solicit input from board members to gauge interest. 6

7. September 2011 The Pistoia AllianceBoard and Membership Update

8. Core Board Member Change 10 Core companies Bi-Annual rotation process AstraZeneca, BMS, GSK, Lundbeck, Pfizer, Roche agreed to continue 1 Seat Vacant as Novartis kindly agreed to step down and 1 Candidate – Merck & Co Decision: Merck & Co are duly elected to Pistoia Alliance board until 2013 AGM. 8

9. Participating Board Member Vote Annual Rotation Process 14 Participating companies 6 Seats vacant (Infosys stepped down and normal rotation process) 7 candidates – we thank them all for standing Candidates: Frank Brown VP and CSO Accelrys Joe Donahue Senior Vice President, Global Sales at Thomson Reuters Life Sciences Alex Drijver, CEO, ChemAxon Sean Eakins, Collaborations Director, Collaborative Drug Discovery Nicholas Lakin, Cognizant Alex Scheer, Director, Informatics & Knowledge Management, Merck Serono Michael Stapleton , General Manager, Informatics at PerkinElmer Decision: Frank, Joe, Alex D, Sean, Alex S, and Michael are duly elected to Pistoia Alliance board until 2012 AGM. 9

10. Pistoia Governance Ramesh Durvasula BMS Alex DrijverChemAxon Frank Brown Accelrys Claus Stie KallesøeLundbeck Bryn Roberts F. Hoffmann-La Roche Alexander ScheerMerck Serono Joe Donahue Thomson Reuters Tom Flores GlaxoSmithKline ChristophBrockel Pfizer Jason Swift AstraZeneca Ingrid AkerblomMerck & Co Sean EakinsCDD Michael StapletonPerkinElmer BoD Operational Team Technical Committee Chair Michael Braxenthaler Roche External Liaison Ashley GeorgeGlaxoSmithKline Treasurer John Wise Executive Director Nick Lynch AstraZeneca President Deborah Ausman Communications Martyn Wilkins Company Secretary Vacant Supported by Working Group Chairs and Operational Team Thanks to Pierre Menard for all his contributions to Pistoia as Technical Committee Chair 10

11. Pistoia Alliance Membership Sept 2011

13. Academics/NGOs

14. CROs

15. Wider Geographic coverage (Asia etc)Can you help with member recruitment? 12

16. September 2011 The Pistoia AllianceProject Portfolio Review

20. Phase 2 launched.

21. RFP published with enhanced user requirements including addressing NGS data.

22. RFP responses expected 23-Sep-11

23. Phase 2 PoC demonstrations at PA User Conference – April 2012Next steps

25. sequencing data for use in the Sequenced Services project

26. £12,000 + VAT @ 20% to manage the prize

27. $15,000 prize money

29. Establish a judging panel

30. State-of-the-art gene sequence data compression tool

31. Project launch – start Q4 2011

32. Entries close end Q1 2012

33. Winners to be announced at the Pistoia Alliance Annual Conference on April 2012.Next steps

37. Two publications submitted end Q3 2011

38. Terminate project.

39. Complete demonstrator implementation

40. Submit publications

41. Transfer learnings to IMI Open PHACTS projectNext steps

44. Elaborated an XML-based query standard – ready for testing

45. Find resource to write and publish a paper highlighting the opportunities and challenges of ELN Query standards.Next steps

48. Identify gaps in life sciences vocabulary standards space

50. Identify and seek funding from interested parties to recruit a qualified consultancy to review vocabulary activities in the Life Sciences R&D domain.

51. Identify leaders across companies to maintain momentum

52. Identify areas for further vocabulary development, either specific initiatives, or as elements of other Pistoia activities

53. Assign priority to those areasNext steps

55. RFP launch meeting completed: 22-Jul-11

57. Appropriately qualified company appointed to run the prize

60. Used at the 3rd Annual Lab Data Mgmt. Conf. London – June-11

62. Draft agenda created

64. Demonstrator to be available by end Aug 2011

67. Reflections on Progress

68. Pistoia Alliance Project Teams - Reflections Slide 21

69. Pistoia Alliance Publications “The Pistoia Alliance - The Sequence Services Project” - Simon Thornber et al. - G.I.T. Laboratory Journal 1-2/2011 “Need for Collaborative Technologies in Drug Discovery” - Chris L. Waller et al. Book Chapter in “Collaborative Computational Technologies for Biomedical Research” – Edited by Sean Ekins et al. Wiley May 2011 “What are the obstacles to innovation in the Pharmaceutical Industry? The Pistoia Alliance responds” – The Pistoia Alliance – Drug Discovery World “Empowering Industrial Research With Shared Biomedical Vocabularies” – Lee Harland et al - Drug Discovery Today in press “ELNs - An Essential Productivity Tool – But Which One to Use” – John Wise - European Pharmaceutical Review - Issue 4, 2011 22

70. September 2011 The Pistoia AllianceProject Portfolio Questionnaire Analysis

71. Project Portfolio Questionnaire – Summary

72. Open Question - 9

73. September 2011 The Pistoia AllianceInformation Ecosystem Workshop (IES) Overview

74. IES Workshop: Logistics

75. Agenda and Deliverables Outline Morning session: What is the IES? Develop common understanding on what the IES should deliver (use cases) Afternoon session: How do we get there? Develop a roadmap of projects and activities White Paper: The Key Concepts of the Information Ecosystem IES Roadmap: Projects and Follow-up activities More info at http://pistoiaalliance.org/2011-Events/infoecoworkshop.html

76. September 2011 The Pistoia AllianceViews of a new member

77. “Thoughts of a new member of the Pistoia Alliance” Presentation to the Pistoia Alliance AGM Nick Trigg, CEO Constellation Technologies 13th Sept 2011 30

78. Constellation Technologies Involvement with Pistoia contributing supplier since 2010 paid up “Participating” member since 2011 “Technology provider” Technology provider with technology from CERN and UK particle physics programme specialising in providing “big data and bioinformatics” expertise to industrial customers. Looking for partners with which to develop next generation products for bioinformatics Delivered solution to Pistoia “Sequence Services Phase 1” Partnership with Microsoft and STFC Demonstrated solution at the Pistoia Users Conference, Boston, April 2011 31

79. Pistoia -An alliance of interested parties Pharmas Large/medium/small Biotechs Academic institutions Technology providers Information providers Infrastructure providers 32 Demand side Supply side

80. Objectives of Pistoia Fundamentally Make more money! Solve complicated problems better/faster How does it do that? Access to customers/suppliers Access to partners/collaborators Latest thinking/trends Opportunity to influence/direct 33

81. How to increase value for members More in = more out Keep it relevant Maintain momentum with innovative projects Work efficiently Same time as other events/Teleconferencing Raise additional funding for projects from other sources Government etc 34

82. How to attract new members It is unique Added value of a special interest “club” More customers or suppliers than normally possible Leverage of everything Money, ideas, technologies, etc 35

83. Summary Recognise that Pistoia is probably unique in the world Keep it going! Realise “failures” are not all bad Manage back into your organisations Don’t let it die slowly through expectation that it will die slowly 36

84. September 2011 The Pistoia AllianceSummary

86. Thanks for your engagement in the coming year! 39